Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Skin Neoplasms × reolysin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Skin Neoplasms 1 Neoplasms 1 Melanoma 1

Interventions

Petrolatum 2 Fluorouracil 2 trametinib 1 talimogene laherparepvec 1 sargramostim 1 reolysin 1 pimonidazole 1 fluoromisonidazole 1 dabrafenib 1 Trimethoprim, Sulfamethoxazole Drug Combination 1 Surgical Procedures, Operative 1 Radiotherapy 1 Radiation 1 Povidone-Iodine 1 Melphalan 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Erlotinib Hydrochloride 1 Clindamycin 1 Clarithromycin 1 Cephalexin 1 Azithromycin 1 Anti-Bacterial Agents 1 Amoxicillin 1 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

University of Leeds

Phase 1/2 Withdrawn

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡